Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal resistance in human ovarian cancer cells

Molecular Cancer Therapeutics

Volumn 3, Issue 7, 2004, Pages 833-838

  Duan, Zhenfeng ^a   Brakora, Katherine A ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; SMALL INTERFERING RNA; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RNA ISOLATION; RNA SEQUENCE; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PACLITAXEL; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 4444275386     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14:2054-60.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Mad 1996;334:1-6.
3. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1-19.
4. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61.
5. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 1990;50:1748-56.
6. Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem 1994;31:1-61.
7. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991;88:547-51.
8. Schurr E, Raymond M, Bell JC, Gros P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 1989;49:2729-33.
9. Rappa G, Lorico A, Liu MC, et al. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 1997;54: 649-55.
10. Arai Y, Masuda M, Sugawara I, et al. Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Leuk Res 1997;21: 313-9.
11. Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86:302-10.
12. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993;268:2946-52.
13. Chaudhary PM, Roninson IB. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 1992;4:281-90.
14. Hannon GJ. RNA interference. Nature 2002;418:244-51.
15. Fjose A, Ellingsen S, Wargelius A, Seo HC. RNA interference: mechanisms and applications. Biotechnol Annu Rev 2001;7:31-57.
16. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999;5:3445-53.
17. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 1999;229:75-81.
18. Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 1987;6:3325-31.
19. Van der Bliek AM, Baas F, Van der Velde-Koerts T, et al. Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 1988;48:5927-32.
20. Nooter K, Sonneveld P, Janssen A, et al. Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 1990;45:626-31.
21. Schinkel AH, Roelofs EM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991;51:2628-35.
22. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:152-6.
23. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
24. Lincke CR, Smit JJ, van der Velde-Koerts T, Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 1991;266:5303-10.
25. Smith AJ, van Helvoort A, van Meer G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000;275:23530-9.
26. Kino K, Taguchi Y, Yamada K, Komano T, Ueda K. Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins. FEBS Lett 1996;399:29-32.
27. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-9.
28. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003;545:144-50.